This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bruker (BRKR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Bruker (BRKR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bruker (BRKR) Misses Q2 Earnings Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of -3.03% and +0.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
BRKR Stock Gains Following the Multi-System Advanced Packaging Order
by Zacks Equity Research
Bruker ships and installs its 15th InSight WLI system as part of a 27-optical metrology unit order tied to AI chip packaging demand.
New Strong Sell Stocks for June 23rd
by Zacks Equity Research
ARCC, BIDU and BRKR have been added to the Zacks Rank #5 (Strong Sell) List on June 23 2025.
Bruker Stock Set to Gain From Acquisition of Austria's biocrates
by Zacks Equity Research
BRKR strengthens its MS-based metabolomics platform with the biocrates deal, boosting investor sentiment.
Bruker Stock to Gain From the Launch of MOVE-T Liquid Dairy Analyzer
by Zacks Equity Research
BRKR unveils the MOVE-T analyzer to boost quality and efficiency in the dairy industry, setting new standards for precision and reliability.
International Markets and Bruker (BRKR): A Deep Dive for Investors
by Zacks Equity Research
Explore Bruker's (BRKR) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Bruker Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Crash
by Zacks Equity Research
Bruker delivers better-than-expected earnings and revenues in the first quarter of 2025.
Compared to Estimates, Bruker (BRKR) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Bruker (BRKR) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bruker (BRKR) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 2.17% and 0.91%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Bruker (BRKR) Q1 Earnings Expected to Decline
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bruker Stock May Benefit Following Its Investment in Ridom GmbH
by Zacks Equity Research
BRKR announces a new partnership with NGS bioinformatics solution provider Ridom GmbH.
Bruker Debuts Fourier 80 Multinuclear Benchtop FT-NMR: Stock to Gain?
by Zacks Equity Research
BRKR's latest innovation offers 1H NMR and a choice of 15 X-nuclei with just one click.
Bruker Announces Groundbreaking 1.3 GHz NMR System, Stock Up
by Zacks Equity Research
BRKR's new 1.3 GHz high-resolution NMR system comes with a stable, standard-bore 54 mm superconducting magnet.
Bruker Introduces Breakthrough d-DNP Polarizer: Stock to Gain?
by Zacks Equity Research
BRKR announces first successful customer installation of novel d-DNP Polarizer at UCSF.
BioSpin's Innovations to Support Bruker Shares, Macro Issues to Ail
by Zacks Equity Research
BRKR NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.
Bruker Stock to Benefit From the Launch of X4 POSEIDON Benchtop XRM
by Zacks Equity Research
BRKR unveils X4 POSEIDON advanced XRM for 3D microscopy in industrial and scientific applications.
Bruker Q4 Earnings & Revenues Surpass Estimates, Stock Falls
by Zacks Equity Research
Bruker delivers better-than-expected earnings and revenues in the fourth quarter of 2024.
Bruker (BRKR) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Bruker (BRKR) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Bruker (BRKR) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 1.33% and 0.91%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Bruker (BRKR) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CALID Arm Growth to Support Bruker Shares Amid Macro Issues
by Zacks Equity Research
BRKR's NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.
BRKR Stock Up on the Launch of LUMOS II ILIM QCL-Based IR Microscope
by Zacks Equity Research
Bruker launches LUMOS II ILIM QCL-based IR microscope for pharma and life science research.
Bruker Adds Another 1.2 GHz NMR System in Switzerland, Stock Climbs
by Zacks Equity Research
Bruker announces a 1.2 GHz NMR spectrometer at the Swiss High-field NMR facility.
Why Is Bruker (BRKR) Up 0.9% Since Last Earnings Report?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.